Latest Rifampicin Stories

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem. Millions of people develop TB every year. Around 13% of cases occur in people living with HIV...

Vanderbilt biochemists have discovered that the process bacteria undergo when they become drug resistant can act as a powerful tool for drug discovery. Their findings – reported this week in the Online Early Edition of the Proceedings of the National Academy of Sciences – should give a major boost to natural products drug discovery – the process of finding new drugs from compounds isolated from living organisms – by substantially increasing the number of novel compounds that...

PARIS and NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide(1) in 2010. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Under the agreement, Sanofi and...

(Ivanhoe Newswire) -- Two research studies suggest that a new automated DNA test for tuberculosis (Xpert MTB/RIF), which can detect TB within 2 hours and has been endorsed by the World Health Organization, can significantly increase TB detection rate compared to other tests, particularly in HIV positive patients who have a high risk of being infected with TB, including multidrug resistant TB.In the first study, led by Stephen Lawn from the Desmond Tutu HIV Centre at the University of Cape...

Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB. That population includes as many as 22 million in sub-Saharan Africa who are already HIV positive and at high risk of also picking up TB, which is...

PARIS, June 29, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it entered into a research collaboration with Weill Cornell Medical College to develop new anti-infectives that aim to shorten the course of treatment of tuberculosis (TB) and provide effective therapies against drug-susceptible and drug-resistant strains of TB. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Under the terms of the collaboration, Sanofi will provide 80,000 chemical...

(Ivanhoe Newswire) -- In patients with newly-diagnosed tuberculosis (TB), use of a combined four-drug, fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a new study."Despite the availability of a highly effective 6-month chemotherapy regimen, worldwide control of tuberculosis is severely impeded by poor treatment completion rates that threaten the emergence of multidrug resistance," according to background information in the...

RNA recycling system gone awry brings MRSA to a haltScientists have discovered a new way to attack dangerous pathogens, marking a hopeful next step in the ever-escalating battle between man and microbe.In a paper published online Feb. 10 in the journal PLoS Pathogens, scientists demonstrate that by stopping bacteria's ability to degrade RNA "“ a "housekeeping" process crucial to their ability to thrive "“ scientists were able to stop methicillin-resistant Staphylococcus aureus...

SUNNYVALE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its Xpert® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), "Rapid Molecular Detection of Tuberculosis and Rifampin Resistance." The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition. Funded and led by the Foundation for Innovative New Diagnostics (FIND), the study...

Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis. The bacterium was identified in a patient in China and is described in a study by researchers at the Johns Hopkins Bloomberg School of Public Health, Chongqing Pulmonary Hospital, Lanzhou University and Fudan University. The researchers determined that the bacteria grew poorly in the absence of the antibiotic rifampin and better...